πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 112 of 173

  1. US 8415302

    Surgical applications for BMP binding protein

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8415294

    Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8414908

    Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8415458

    Modified vitamin K-dependent polypeptides

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8415457

    Modified vitamin K-dependent polypeptides

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8415400

    Cross-linked ionic core micelles

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8415343

    Compositions and methods for inhibiting the proliferation of cells

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8415384

    Reducing myocardial reperfusion injury by the combination therapy of protein kinase A activation and B1-adrenergic receptor blockade

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8415323

    MicroRNAs for inhibiting viral replication

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8415293

    Peptide mediators of cholesterol efflux

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8414911

    Photochemical therapy to affect mechanical and/or chemical properties of body tissue

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8409859

    Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8410140

    Anesthetic methods and compositions

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8409126

    Selective cytopheresis devices and related methods thereof

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8409548

    Administration of growth factors for the treatment of CNS disorders

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8404635

    Orally administered peptides synergize statin activity

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8404817

    Humanized anti-prostate stem cell antigen monoclonal antibody

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8404631

    Compositions and methods for the delivery of oxygen

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8404806

    Isolated BRCA1 peptides and method of use

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8404650

    Methods of treating cancer with doxazolidine and prodrugs thereof

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8404632

    Compositions and methods for the delivery of nitric oxide

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8403876

    Indwelling heat exchange catheter and method of using same

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8399412

    Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8399425

    Alleviating neuropathic pain with EETs and sEH inhibitors

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8399421

    Treatment for neuropathic pain due to spinal cord injury

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8399025

    Polyamine modified particles

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8398989

    Human cystathionine Ξ²-synthase variants and methods of production thereof

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8399609

    Treating or preventing extracellular matrix build-up

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8399018

    Controlled release ion channel modulator compositions and methods for the treatment of otic disorders

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8399428

    Nucleosides with antiviral and anticancer activity

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8394620

    Two-component genome flavivirus and uses thereof

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8394377

    Methods for treating cancer using combination therapy

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8394375

    Antibodies for amyloid specific peptides

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8394794

    Therapeutic compounds

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8394788

    Phenylsulfoxyoxazole compound inhibitors of urea transporters

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8394583

    VH4 codon signature for multiple sclerosis

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8394357

    Optical determination of glucose utilizing boronic acid adducts

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8388930

    Diagnosis and assessment of skeletal related disease using calcium 41

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8389736

    Compounds having activity in correcting mutant-CFTR processing and uses thereof

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8389679

    Targeted antimicrobial moieties

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8389478

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8389232

    Fluorescence detection of poison oak oil

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8388643

    Bioabsorbable polymeric implants and a method of using the same to create occlusions

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8383132

    Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8383805

    RNAi modulation of SCAP and therapeutic uses thereof

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8383580

    Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8383576

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8383360

    Methods of diagnosing and treating autism

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.